Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Minodronic Acid

A third-generation bisphosphonate that slows bone resorption by inhibiting the enzyme farnesyl pyrophosphate synthase; it was first marketed in Japan in 2009 for osteoporosis. This family brings together the active ingredient, labelled standards and other impurities.

Did you know?Besides slowing bone loss it blocks P2X2/3 receptors, which are involved in pain signalling: an action that may help reduce osteoporosis-related back pain.

Minodronic AcidGo to the active ingredient →

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.